Drug Trial Radar · NCT05039177
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Sep 20, 2021
Primary completion
Aug 15, 2025
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.
Conditions
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ERAS-007Drug
Administered orally
EncorafenibDrug
Administered orally
CetuximabDrug
Administered via intravenous infusion
PalbociclibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
- Maximum Tolerated Dose (MTD)Time frame: Study Day 1 up to Day 29
- Recommended Dose (RD)Time frame: Study Day 1 up to Day 29
- Adverse EventsTime frame: Assessed up to 24 months from time of first dose
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)
Birmingham, Alabama
City of Hope
Duarte, California
University of California Irvine College of Medicine
Orange, California
UCSF Mount Zion Medical Ctr
San Francisco, California
The Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Cancer Institute
Detroit, Michigan
Washington University (Siteman Cancer Center)
St Louis, Missouri
Duke Cancer Institute
Durham, North Carolina
Stephenson Cancer Center
Oklahoma City, Oklahoma
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.